New cell therapy targets hard-to-treat blood disorders

NCT ID NCT07072247

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment called RN1201 for people with certain blood disorders caused by the immune system attacking the body's own cells. The treatment involves giving patients specially designed immune cells after a short course of chemotherapy to weaken the existing immune system. The goal is to see if RN1201 is safe and can help raise platelet counts and reduce bleeding in patients who have not responded to standard therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY IMMUNE-MEDIATED PLATELET TRANSFUSION REFRACTORINESS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic Recurrence thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY IMMUNE-MEDIATED PLATELET TRANSFUSION REFRACTORINESS RELAPSED OR REFRACTORY IMMUNE THROMBOCYTOPENIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, China

Contact Phone: •••-•••-•••• Email: •••••@•••••